Revolution Medicines (RVMD) Change in Receivables (2020 - 2024)
Revolution Medicines (RVMD) posted quarterly Change in Receivables of -$1.3 million for Q1 2024, down 84.96% year-over-year from -$8.3 million in Q2 2023, and down 232.7% quarter-over-quarter from $945000.0 in Q4 2023.
Powered by 
Analysis
Revolution Medicines (RVMD) Change in Receivables (2020 - 2024) Analysis & Trends
Revolution Medicines' Change in Receivables history runs 5 years deep, the most recent figure standing at -$1.3 million for Q1 2024.
- In Q1 2024, Change in Receivables fell 84.96% year-over-year to -$1.3 million; the TTM figure through Dec 2024 stood at -$1.3 million (up 63.32% YoY), while the FY2024 annual figure was -$1.3 million, up 63.32% from the prior year.
- Change in Receivables for Q1 2024 stood at -$1.3 million, down from $945000.0 in the prior quarter.
- The five-year high for Change in Receivables was $2.0 million in Q3 2020, with the low at -$2.9 million in Q4 2020.
- The 5-year median for Change in Receivables is -$678000.0 (2023), against an average of -$513941.2.
- The sharpest annual moves came in 2021 and 2023: Change in Receivables surged 508.01% in 2021, then sank 716.18% in 2023.
- Revolution Medicines' Change in Receivables stood at -$2.9 million in 2020, then jumped by 48.97% to -$1.5 million in 2021, then jumped by 82.0% to -$267000.0 in 2022, then soared by 453.93% to $945000.0 in 2023, then tumbled by 232.7% to -$1.3 million in 2024.
- Business Quant data shows RVMD's Change in Receivables at -$1.3 million in Q1 2024, $945000.0 in Q4 2023, and -$2.2 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 73.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | 945,000.00 |
| Sep 30, 2023 | -2.20 Mn |
| Jun 30, 2023 | -1.49 Mn |
| Mar 31, 2023 | -678,000.00 |
| Dec 31, 2022 | -267,000.00 |
| Sep 30, 2022 | -684,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Mar 31, 2022 | -546,000.00 |
| Dec 31, 2021 | -1.48 Mn |
| Sep 30, 2021 | 885,000.00 |
| Jun 30, 2021 | -1.04 Mn |
| Mar 31, 2021 | 1.17 Mn |
| Dec 31, 2020 | -2.91 Mn |
| Sep 30, 2020 | 1.97 Mn |
| Jun 30, 2020 | -1.12 Mn |
| Mar 31, 2020 | -287,000.00 |